- Lesion acquired in childhood (at <21 years of age)
- Any lesion location except CNS
- Any malignant tumor or metastasis
- Any benign lesion (e.g. desmoids, venous or lymphatic vascular anomalies, aneurysmal
bone cysts, osteoid osteoma, tongue hypertrophy, or painful neuropathy)
- Patients with malignant disease have had histologic confirmation of disease at
- ≥ 90 day life expectancy
- Potential benefit of RFA outweighs risk as determined by PI
- Other local tumor control measures are not recommended for malignant lesion based on
review in multidisciplinary team conference or the patient refuses recommended local
tumor control measures
- The patient is not expected to become short of breath at rest after RFA (forced vital
capacity ≥33% of normal by pulmonary function tests) if pulmonary RFA is considered
- Patients with uncontrolled infection.
- Patients with co-morbidities affecting inclusion criteria above.
- Patients who are pregnant and/or breastfeeding.
- Patients who had a change in chemotherapy within one month before RFA
- Patients who have planned change in chemotherapy and/or radiation therapy (to same
site as RFA) interventions within the first three months following RFA.
- Patients should not be considered for pulmonary RFA if they have poorly compliant
lungs (recently required mechanical ventilation) or require supplemental oxygen.